Schlingensiepen, K. H. and Schlingensiepen, R. and Steinbrecher, Andreas and Hau, Peter and Bogdahn, Ulrich and Fischer-Blass, B. and Jachimczak, P. (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. CYTOKINE & GROWTH FACTOR REVIEWS, 17 (1-2). pp. 129-139. ISSN 1359-6101, 1879-0305
Full text not available from this repository. (Request a copy)Abstract
TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta 2 by the antisense oligodeoxynuclcotide AP 12009. After providing preclinical proof of concept, we assessed safety and efficacy of AP 12009 in clinical phase I/II open-label dose escalation studies in high-grade glioma patients. Median survival time after recurrence exceeded the up to date literature data for chemotherapy. A phase I/II Study in pancreatic carcinoma and malignant melanoma is currently ongoing. Our results implicate targeted TGF-beta 2 suppression as a promising therapeutic approach for malignant tumor therapy. (c) 2005 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-FACTOR-BETA; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; PROSTATE-CANCER; MALIGNANT GLIOMA; NEURONAL DIFFERENTIATION; DISEASE PROGRESSION; MULTIPLE-MYELOMA; RNA EXPRESSION; BREAST-CANCER; TGF-beta; high-grade gliomas; pancreatic carcinoma; malignant melanoma; antisense oligodeoxynucleotides |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Petra Gürster |
| Date Deposited: | 10 Feb 2021 11:29 |
| Last Modified: | 10 Feb 2021 11:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/34972 |
Actions (login required)
 |
View Item |
